RESUMEN
OBJECTIVES: Lupus nephritis (LN) is a frequent complication of systemic lupus erythematosus (SLE). Severe (proliferative) forms of LN are treated with induction immunosuppressive therapy (IST), followed by maintenance IST, to target remission and avoid relapses. The optimal duration of maintenance IST is unknown. The WIN-Lupus trial tested whether IST discontinuation after 2â3 years was non-inferior to IST continuation for two more years in proliferative LN. METHODS: WIN-Lupus was an investigator-initiated multicentre randomised controlled trial. Patients receiving maintenance IST with azathioprine or mycophenolate mofetil for 2-3 years, and hydroxychloroquine, were randomised (1:1) into two groups: (1) IST continuation and (2) IST discontinuation. The primary endpoint was the relapse rate of proliferative LN at 24 months. Main secondary endpoints were the rate of severe SLE flares, survival without renal relapse or severe flare, adverse events. RESULTS: Between 2011 and 2016, 96 patients (out of 200 planned) were randomised in WIN-Lupus: IST continuation group (n=48), IST discontinuation group (n=48). Relapse of proliferative LN occurred in 5/40 (12.5%) patients with IST continuation and in 12/44 (27.3%) patients with IST discontinuation (difference 14.8% (95% CI -1.9 to 31.5)). Non-inferiority was not demonstrated for relapse rate; time to relapse did not differ between the groups. Severe SLE flares (renal or extrarenal) were less frequent in patients with IST continuation (5/40 vs 14/44 patients; p=0.035). Adverse events did not differ between the groups. CONCLUSIONS: Non-inferiority of maintenance IST discontinuation after 2â3 years was not demonstrated for renal relapse. IST discontinuation was associated with a higher risk of severe SLE flares. TRIAL REGISTRATION NUMBER: NCT01284725.
Asunto(s)
Lupus Eritematoso Sistémico , Nefritis Lúpica , Azatioprina/uso terapéutico , Humanos , Terapia de Inmunosupresión , Inmunosupresores/uso terapéutico , Lupus Eritematoso Sistémico/inducido químicamente , Nefritis Lúpica/tratamiento farmacológico , Ácido Micofenólico/uso terapéutico , Recurrencia , Resultado del Tratamiento , DesteteAsunto(s)
Proteína C-Reactiva/metabolismo , Eosinofilia/diagnóstico , Granulomatosis con Poliangitis/diagnóstico , Síndrome Hipereosinofílico/diagnóstico , Anticuerpos Anticitoplasma de Neutrófilos/metabolismo , Síndrome de Churg-Strauss/diagnóstico , Diagnóstico Diferencial , Femenino , Humanos , Masculino , Persona de Mediana EdadAsunto(s)
Edema/genética , Mutación Missense , Mutación Puntual , Receptores Tipo I de Factores de Necrosis Tumoral/genética , Proteína C-Reactiva/análisis , Edema/sangre , Etanercept , Extremidades , Cara , Humanos , Inmunoglobulina G/uso terapéutico , Recuento de Leucocitos , Masculino , Persona de Mediana Edad , Fenotipo , Receptores del Factor de Necrosis Tumoral/uso terapéutico , Receptores Tipo I de Factores de Necrosis Tumoral/antagonistas & inhibidores , Receptores Tipo I de Factores de Necrosis Tumoral/fisiología , Recurrencia , SíndromeRESUMEN
Chronic graft-versus-host disease (GVHD) sometimes mimics autoimmune diseases. We report the case of a 39-year-old patient who presented atypical polymyositis without elevated creatinine phosphokinase, related to a chronic GVHD following interruption of immunosuppressive treatment. Treatment with cyclosporine and corticosteroids resulted in complete and sustained remission of the polymyositis. The symptoms of chronic GVHD-related polymyositis are indistinguishable from those of idiopathic polymyositis. The context of transplantation and a decrease or interruption of prophylaxis suggest the diagnosis of GVHD-related polymyositis, especially if other manifestations of GVHD are associated. A suitably adapted treatment (association of corticotherapy and cyclosporine) improves polymyositis, and in most cases, a normal clinical state is achieved even if the symptoms were severe.
Asunto(s)
Enfermedad Injerto contra Huésped/complicaciones , Polimiositis/etiología , Corticoesteroides/uso terapéutico , Adulto , Ciclosporina/uso terapéutico , Humanos , Inmunosupresores/uso terapéutico , Masculino , Polimiositis/tratamiento farmacológico , Polimiositis/inmunologíaRESUMEN
The formation of advanced glycation end products (AGEs) is a result of the non-enzymatic reaction between sugars and free amino groups of proteins. AGEs, through interacting with their specific receptor for AGEs (RAGE), result in activation of pro-inflammatory states and are involved in numerous pathologic situations. The soluble form of RAGE (sRAGE) is able to act as a decoy to avoid interaction of RAGE with its pro-inflammatory ligands (AGEs, HMGB1, S100 proteins). sRAGE levels have been found to be decreased in chronic inflammatory diseases including atherosclerosis, diabetes, renal failure and the aging process. The use of measuring circulating sRAGEs may prove to be a valuable vascular biomarker and in this review, we describe the implications of sRAGE in inflammation and propose that this molecule may represent a future therapeutic target in chronic inflammatory diseases.